Razack R, van Wyk A C, Schubert P T, Pelletier D, Foulkes W D, Njovu C, Conradie W, Hoosain F
Division of Anatomical Pathology, Tygerberg Hospital, National Health Laboratory Service, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Department of Human Genetics, Medicine, McGill University, Montreal, Quebec, Canada.
Diagn Cytopathol. 2025 Oct;53(10):E181-E189. doi: 10.1002/dc.25504. Epub 2025 Jul 13.
Thyroblastoma is a rare, aggressive thyroid neoplasm newly classified in the 2022 WHO Classification of Endocrine Tumors. It is characterized by embryonal, multilineage morphology and DICER1 mutations. Fewer than 15 well-characterized cases have been reported, with limited cytological descriptions.
A 19-year-old pregnant woman presented with a rapidly enlarging right thyroid mass. Fine needle aspiration biopsy (FNAB) revealed a highly cellular, triphasic aspirate composed of primitive epithelium arranged in macrofollicular structures, spindled mesenchymal cells within a myxoid matrix, and small round blastemal cells. Immunocytochemistry showed TTF-1 and PAX8 positivity in epithelial cells, synaptophysin and SALL4 in blastemal cells, and myogenin in both spindled and blastemal components, supporting a cytological diagnosis of thyroblastoma. She underwent total thyroidectomy and neck dissection during the second trimester. Histology confirmed thyroblastoma with extensive lymph node metastases. Chemotherapy was initiated during pregnancy but discontinued due to neutropenic complications. She delivered a healthy infant and remained disease-free at her 12-month follow-up.
Next-generation sequencing of tumor DNA revealed two somatic DICER1 mutations: a known hotspot missense mutation, c.5437G>C; p.E1813Q, and a novel splice-site variant, c.734+1G>T, predicted to disrupt normal splicing and protein function. No pathogenic variants were found in germline DNA, supporting a somatic origin.
This case expands the cytological and molecular spectrum of thyroblastoma and highlights the value of FNAB in early recognition. Awareness of this rare entity and its diagnostic features is essential to avoid misclassification and ensure timely management. The novel DICER1 splice-site mutation further contributes to the evolving molecular landscape of thyroblastoma.
甲状腺母细胞瘤是一种罕见的侵袭性甲状腺肿瘤,在2022年世界卫生组织内分泌肿瘤分类中被重新分类。它具有胚胎性、多谱系形态学特征以及DICER1突变。目前报道的特征明确的病例不足15例,细胞学描述有限。
一名19岁孕妇因右侧甲状腺肿块迅速增大前来就诊。细针穿刺活检(FNAB)显示吸出物细胞丰富,呈三相,由排列成大滤泡结构的原始上皮、黏液样基质中的梭形间充质细胞以及小圆形胚基细胞组成。免疫细胞化学显示上皮细胞中TTF-1和PAX8阳性,胚基细胞中突触素和SALL4阳性,梭形和胚基成分中肌生成素阳性,支持甲状腺母细胞瘤的细胞学诊断。她在孕中期接受了全甲状腺切除术和颈部清扫术。组织学证实为甲状腺母细胞瘤伴广泛淋巴结转移。孕期开始化疗,但因中性粒细胞减少并发症而停药。她产下一名健康婴儿,在12个月的随访中无疾病复发。
肿瘤DNA的二代测序显示两个体细胞DICER1突变:一个已知的热点错义突变,c.5437G>C;p.E1813Q,以及一个新的剪接位点变异,c.734+1G>T,预计会破坏正常剪接和蛋白质功能。在种系DNA中未发现致病变异,支持体细胞起源。
该病例扩展了甲状腺母细胞瘤的细胞学和分子谱,突出了FNAB在早期识别中的价值。认识到这种罕见实体及其诊断特征对于避免误诊和确保及时治疗至关重要。新的DICER1剪接位点突变进一步丰富了甲状腺母细胞瘤不断演变的分子格局。